Ignite Creation Date:
2024-05-06 @ 2:08 AM
Last Modification Date:
2024-10-26 @ 11:14 AM
Study NCT ID:
NCT01970865
Status:
COMPLETED
Last Update Posted:
2023-06-07
First Post:
2013-10-16
Brief Title:
A Study Of PF-06463922 An ALKROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
PHASE 12 STUDY OF PF-06463922 AN ALKROS1 TYROSINE KINASE INHIBITOR IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER HARBORING SPECIFIC MOLECULAR ALTERATIONS
Status:
COMPLETED
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
True
If Expanded Access, NCT#:
NCT03127618
Has Expanded Access, NCT# Status:
APPROVED_FOR_MARKETING
Acronym:
None
Brief Summary:
Phase 1 and 2 trial to study the safety pharmacokinetics pharmacodynamics patient reported outcomes and efficacy of PF-06463922 in ALK advanced non-small cell lung cancer patients and ROS1 advanced non small cell lung cancer patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2013-002620-17 | EUDRACT_NUMBER | None | None |